RecruitingPhase 2NCT05725837

Effects of Paroxetine on Cardiovascular Function in Septic Patients

Effects of Paroxetine on Cardiovascular Function in Septic Patients: a Randomized Placebo Controlled Trial

Sponsor

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Enrollment

92 participants

Start Date

Jun 10, 2023

Study Type

INTERVENTIONAL

Conditions

Sepsis Septic Shock

Summary

It is known that septic shock is characterized by arterial hypotension, decreased peripheral vascular resistance and hyporeactivity to vasoconstrictor agents, with NO being an important mediator of this organ dysfunction. Data in the literature have shown that hyporeactivity to catecholamines is associated with a decrease in the density of α and ß receptors in the aorta and heart, respectively, as well as an increase in GRK2 levels and that NO contributes to the increase of this kinase in sepsis . Based on this, it is hypothesized that cardiac dysfunction and decreased peripheral vascular resistance observed in sepsis may result from an increase in GRK2 activity and/or expression and its inhibition may be a relevant therapeutic target in septic shock patients. Based on this line, a measurable clinical benefit of paroxetine through the regulation of GRK2 expression in patients with septic shock is postulated.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Patient over 18 years of age;
Patient diagnosed with septic shock for less than 48 hours and using a minimum dose of noradrenaline (0.01 mcg/kg/min);
Patients and/or legal guardians who consented to participate in the study through the free and informed consent term before randomization.

Exclusion Criteria5

Pregnant women;
Patients with inability to use the gastrointestinal tract;
Patients with known intolerance to paroxetine and/or fluoxetine;
Patients on concomitant use of medications that may potentiate the occurrence of serotonin syndrome (tramadol, citalopram, escitalopram, sertraline, desvenlafaxine, venlafaxine, duloxetine, sibutramine, bupropion, amitriptyline, nortriptyline, lithium);
Patients in end-of-life care or with an expected survival of less than 24 hours at the time of eligibility

Interested in this trial?

Get notified about updates and connect with the research team.